Hemolytic disease of the newborn (HDN), also called erythroblastosis fetalis, is a blood disorder that occurs when the blood types of a mother and baby are incompatible. Our Blood Disorders Center provides comprehensive treatment and management of HDN.
- HDN is relatively uncommon, affecting approximately 4,000 babies a year in the United States.
- It is more likely to occur during a mother’s second or subsequent pregnancy.
- There are two causes, Rh incompatibility and ABO incompatibility.
- HDN due to Rh incompatibility occurs more frequently.
- HDN can be treated during pregnancy or after the baby is born.
- It is very preventable.
Our patients with Hemolytic disease of the newborn (HDN) are treated through the Blood Disorders Center at Dana-Farber/Boston Children's Cancer and Blood Disorders Center, an integrated pediatric hematology and oncology partnership between Dana-Farber Cancer Institute and Boston Children’s Hospital.